Home > Boards > US Listed > Biotechs > Peregrine Pharmaceuticals (PPHM)

From today's online issue of the NCI Cancer Bulletin.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
freethemice Member Profile freethemice  
Tuesday, July 24, 2012 10:41:53 PM
Re: None Post # of 124077 
From today's online issue of the NCI Cancer Bulletin.
I think Peregrine should move ahead on breast cancer as soon as possible.
http://www.cancer.gov/ncicancerbulletin/072412/page12#c

Also in the Journals: No Overall Survival Benefit from Bevacizumab in Breast Cancer, Meta-Analysis Shows

A meta-analysis has shown that adding bevacizumab (Avastin) to chemotherapy may prolong progression-free survival in women with metastatic breast cancer, but the drug has no significant effect on overall survival or quality of life. The findings were published July 11 in the Cochrane Database of Systematic Reviews.
Researchers analyzed data from seven randomized trials involving more than 4,000 women with metastatic breast cancer. In the trials, treatment-related deaths were lower in women receiving bevacizumab, even though the drug increases the risk of serious adverse events that can lead to death.
“Because of the lack of effect on overall survival and quality of life,” the researchers concluded, “it is…controversial whether bevacizumab is associated with a true patient benefit [despite] the increase in progression-free survival.”


Peregrine Pharmaceuticals (PPHM) Stock Trading Info:
Peregrine Pharmaceuticals PPHM Stock Quote Peregrine Pharmaceuticals PPHM Stock Charts Peregrine Pharmaceuticals PPHM Financial
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist